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1 ABBREVIATIONS 
 
aCSF    artificial cerebrospinal fluid 
ADR    adverse drug reaction 
BF    Bayesian Forecasting 
CD    conventional dosing 
dphCF   calculated free phenytoin 
dphF    measured free phenytoin concentration in serum 
dphT    total phenytoin in serum 
FDA    Food and Drug Administration 
fF    free fraction (of a drug) 
GC    gas chromatography 
GC-MS   gas chromatography – mass spectrometry 
ICU    intensive care unit 
IS    internal standard 
ISO    International Organization for Standardization 
IV    intravenous 
LOD    limit of detection 
LOQ    limit of quantification 
MPPH   5-(p-methylphenyl)-5-phenylhydantoin (IS); C16H14N2O2 
MS    mass spectrometry 
PD    Pharmakodynamics 
PHT    Phenytoin (5, 5-Diphenylhydantoin); C15H12N2O2 
PK    Pharmacokinetics 
QC    quality control 
RSD    relative standard deviation 
RT    retention time 
SD    standard deviation 
SPC    summary of product characteristics 
SPE     solid phase extraction 
SST    system suitability test 
TDM    Therapeutic Drug Monitoring 
TSMH    trimethylsulfonium hydroxide 
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2 INTRODUCTION 
 
The importance of Phenytoin in the prevention and therapy of epilepsy 
Epilepsy is the most common serious neurological condition affecting an estimated 
50 million people (1% of the world population) worldwide [1-2]. The annual incidence 
ranges from 20 to 70 cases per 100’000, and the prevalence is 0.4 to 0.8% [1].  
The major goal in epilepsy is to stop seizures or to minimize their frequency and also 
to have minimal concurrent undesirable side-effects [2].  
Generalized epilepsies occur in approximately one-third of patients [1]. Phenytoin 
(PHT) is one of the most efficacious, oldest, and widely prescribed anticonvulsants 
for the treatment of epilepsy [3]. PHT influences the voltage-activated sodium, 
potassium and calcium channels [1].  
 
Different studies showed that antiepileptic prophylaxis with PHT in adults with severe 
traumatic brain injuries before and after neurosurgical intervention is effective, 
whereas the risk for an early (until seven days after the neurosurgical intervention) 
posttraumatic seizure after acute, traumatic brain injuries can be diminished 
significantly [4-7]. 
The use of antiepileptic drugs to treat patients who have developed post-traumatic 
epilepsy is standard [8]. Prophylactic treatment with PHT, beginning with an IV 
loading dose, should be initiated as soon as possible after injury to decrease the risk 
of post-traumatic seizures occurring within the first seven days [8]. PHT is often used 
as antiepileptic (study) drug because it is available as a parenteral formulation (rapid 
loading dose), and its use in the management of acute seizures is widely established 
with respect to both efficacy and safety and the drug is authorized in this indication. 
[9-10]. PHT is the only antiepileptic for which an optimal range of serum 
concentrations (therapeutic range) has been defined clearly and is effective in 
preventing early seizures after acute brain injury [4, 11].  
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Chemical and physical characteristics of PHT 
Chemically, PHT is a hydantoin derivative (5,5-Diphenylhydantoin) (see fig. 1).  
 
Figure 1: Chemical structure of PHT [12].  
 
PHT is a colour- and odourless powder with a melting point between 292 and 299°C 
[13]. The substance is an acid with a pKa-value of 8.33 [12]. The chemical 
characteristics of PHT and PHT-sodium respectively are shown in table 1. 
 
Tab. 1: Chemical characteristics of PHT and PHT-sodium: 
Organoleptic characteristics PHT is a white, crystalline, odourless and 
flavourless powder. The sodium salt is 
also white, crystalline, and lightly 
hygroscopic, with a bitter, soapy flavour 
[14] 
Chemical structure C15H12N2O2 
Molecular weight 252.3 g/mol (PHT) 
274.2 g/mol (PHT-sodium) 
Solubility < 20 µg/mL [15].  
pKa 8.33 (weak acid) [14] 
 
Pharmacology 
Pharmacokinetics 
The pharmacokinetic parameters of PHT are shown in table 2 [16].  
 
Table 2: Pharmacokinetic parameters of PHT:  
Absolute oral bioavailability 85% [17] 
Protein binding 85-95% mostly albumin 
Volume of distribution 0.8 L/kg [18] 
“Half-life” 30 hours1 [19] 
Clearance 0.016-0.042 L/kgh [14]  
Q0 (extrarenal eliminated bioavailable 
dosis-part if normal kidney-function) 
1 [19] 
Therapeutic range 40-80 µmol/L (10-20 µg/mL) 
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1 PHT has a nonlinear kinetic; that means the half-life increases with larger doses. 
Indicated is a typical half-life for therapeutic doses.  
 
Metabolism 
PHT is almost completely metabolised in the liver (hepatic oxidation); less than 5% of 
a dosage is excreted unchanged. The metabolites have no important anticonvulsive 
effect [20-21]. The responsable enzymes are cytochromes, above all CYP2C9 and 
CYP2C19. The range of enzyme saturation can be exceeded even in therapeutic 
dosing, which results in a nonlinear correlation between the dosage and the serum 
levels [22].  
The pharmacokinetics of PHT is already in normal dosages complex because of a 
non-linear, saturable Michaelis-Menten kinetic and because of the interindividual, 
genetic differences in the metabolism (see figure 2). 
v   =   vmax * [S] 
 
                      Km + [S] 
 
 
 
v  =  metabolizing ratio [mg/d] 
vmax  =  maximal capacity of the metabolizing enzyme system [mg/d] 
Km Michaelis-Constant (concentration of the substrate by half enzyme-saturation) 
[mg/L] 
[S] = substrate- and PHT-concentration in the Steady-State respectively [mg/L] 
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Fig. 2: Michaelis-Menten kinetics. Relation between metabolizing ratio (v) and substrate-
concentration [S] of an enzym-katalytic reaction after Michaelis and Menton; shown is the 
example of PHT. vmax is the maximal capacity of the metabolizing enzyme system. The 
concentration of the substrate by half enzyme-saturation is called Michaelis-Menten-constant 
(Km). Up to this point (6 mg/L) the kinetic is linear. The therapeutic range of PHT is between 10-
20 mg/L (40-80 µmol/L). 
 
PHT shows a large interindividual variability in vmax and Km. The values of Km are 4-6 
mg/L and vmax 6-8 mg/kg/day respectively [14].   
 
Total drug concentrations versus free drug concentration 
Total blood drug concentration consists of a protein-bound and free (unbound) 
fraction. Most drugs are bound to serum proteins to a various extent. Only unbound 
or free drug is pharmacologically active [23].  
Normally total drug is measured for therapeutic drug monitoring (TDM), because 
there is equilibrium between bound and free drugs, and concentration of free drug 
can be predicted from total drug concentration [23]. Free drug monitoring is not a 
routine procedure in clinical laboratories due to technical difficulties and lack of 
established reference ranges for free drugs [23-24]. Furthermore the unbound 
fraction has to be separated from the bound fraction (e.g. dialysis, ultrafiltration) [23-
26]. In general strongly bound protein drugs (> 80%) are candidates for free drug 
concentration determination.  
 
 
Free PHT concentration 
Traditionally used techniques to determine the free drug concentration are the 
equilibrium dialysis (microdialysis), or the ultrafiltration (with devices with a cut-off-
filter) [24-25, 27].  
 
The free fraction (fF) of a drug is calculated as: 
 
 
  
       unbound drug concentration 
fF = 
                 total drug concentration 
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The fF is the percentage of the whole drug concentration, which is not bound to 
proteins (e.g. plasma protein binding = 99% Æ fF = 0.01) [28].  
The therapeutic range for the free PHT concentration in the serum is narrow as well 
(1-2 mg/L and 4-8 µmol/L respectively). The critical value for toxicity is > 2 mg/mL. 
Sometimes the therapeutic range of free PHT is indicated as percentage of total 
PHT; it should be between 6 and 12% of total PHT [29], which makes the TDM of the 
fF necessary in variable albumin concentration to make the therapy efficacy and to 
avoid toxicity. TDM of unbound (free) drugs belongs due to highly technical and time-
consuming efforts and costs not to the routinely done measurements in clinical 
laboratories and therefore requires a rational indication.  
 
 
Pharmacodynamic 
The antiepileptic effect of PHT derives from the blockade of voltage-dependent 
sodium channels in the neuronal cell-membrane (see fig. 3). Thus, rapid potentials 
along the axons can be interrupted and repeated unloading can be suppressed [14, 
30].  
Characteristically for the effect of PHT is the dependence of the action from the 
opening-probability of a channel (so called use-dependance) [31].  
 
 
 
Fig. 3: Schematic mechanism of action of PHT [32]. 
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Therapeutic Drug Monitoring (TDM) of PHT 
There are many reasons for a regular TDM while treatment with PHT:  
- Correlation between plasma-concentration and reduction of clinical and 
encephalographic symptoms of epilepsy. [33]. 
- Because of long-term epilepsy treatment, the specific characteristics and 
pharmacokinetics of the antiepileptics, the TDM has become invaluable in the 
optimization of the treatment; a continuing TDM guarantees the efficacy and 
prevents in the meantime the toxicity of the antiepileptic treatment [34-36]. 
 
A good and suitable TDM is dependent on rapid, sensitive, and specific analytical 
techniques. The control of the individual PHT serum levels and the dose adjustment 
are nowadays established routinely to maintain an efficacious and compliant long-
time therapy. TDM as far as PHT is concerned is very important because its 
characteristics fulfil TDM requirements: 
- narrow therapeutic index 
- non-linear, saturable Michaelis-Menten pharmacokinetics 
- interindividual, genetic differences in metabolism 
- correlation between blood serum level and toxicity 
- long-time therapy 
- drug-interactions 
 
 
Bayesian Forecasting 
 
Population data for the calculation of the individual maintenance dose are shown in 
tab. 3 [37]. 
 
Tab. 3: Population data for the calculation of the individual maintenance dose of PHT 
[37]:  
Parameter Standard deviation 
vmax 32.42 mg * (body weight) 0.6 
415 mg/d for a 70 kg weight patient 
Vvmax 20% 
Km 5.7 mg/L VKm 51% 
Vd 1 L/kg VVd 23% 
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The following parameters must be known for the individual dose-calculation: 
- body weight of the patient 
- dosage as IV bolus or as oral maintenance dose for the appropriate given 
time-point 
- trough level at the given time-point 
 
With this data, the following parameters can be calculated: 
- patient parameters (vmax, Km, Vd) ± 68% confidence interval 
- recommended 12 and 24 hours maintenance dose (oral or IV) for reaching the 
aimed steady-state-level 
- prediction of the serum level at the time-point of the next determination 
 
As PHT has a non-linear kinetic, the individual maintenance dose in the Bayesian 
forecasting program is calculated with a method with integrated Michaelis-Menten-
Kinetic [38].  
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3 AIMS OF THE THESIS 
 
In a first and most important part of the investigation, a long-term retrospective 
evaluation was intended on the totality of PHT patients receiving TDM with different 
support in an acute care teaching hospital. An evaluation of PHT treatment measured 
by achieving therapeutic PHT serum levels in two groups of patients was compared. 
In one group physicians and nurses were supported by a round the clock pharmacy 
service - providing guidelines, teaching and information for a rapid IV loading PHT 
medication regimen with individual dose calculation using Bayesian Forecasting (BF) 
algorithms (BF group) after the PHT TDM measurement. In the other group of non-
supported patients, only SPC nomogram-related conventional prescribing material 
was available. 
In addition, the influence of patients’ variables like gender and age should be 
investigated and validated in the BF group. 
 
In a second subgroup investigation, the usefulness of the Sheiner-Tozer algorithm 
was evaluated to calculate the free PHT dose fraction using total PHT serum levels in 
unselected patients with low albumin (≤35 g/L) in the above long-term investigation.  
In a third part, the assessment to correlate PHT blood serum levels, with “brain PHT 
levels” representing the site of action of PHT, available from extracellular fluid from 
microdialysate in neurosurgical patients, was aimed.  
In a first step, a sensitive analytical method with GC-MS was intended to measure 
(free) PHT in “aqueous” patient samples. A simple and effective sample extraction 
method had to be included for different biological matrices (blood, dialysates, and 
saliva). Indicators for the sensitivity had to be calculated [limit of detection (LOD) and 
limit of quantification (LOQ)]. Reproducibility, suitability of calibration, stability of PHT 
and matrix effects had to be addressed.  
Validation according to International Organization for Standardization (ISO) 17025 in 
the corresponding investigation with samples from patients (clinical trials) was aimed 
for the analytical method. 
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4 OVERALL SUMMARY OF THE THESIS 
 
PHT is one of the mostly used and well established anticonvulsants for the treatment 
of epilepsy and a standard in the antiepileptic prophylaxis in adults with severe 
traumatic brain injuries before and after neurosurgical intervention.  
Its therapeutic use is challenging as PHT has a narrow therapeutic range and shows 
non-linear kinetics with a wide interindividual variability in clearance (CL): 
        Vmax 
CL = ----------- 
        Km + C 
 
Vmax (6-8 mg/kg/day), Km (4-6 mg/L); C: plasma conc [1, 2]. 
 
It is extensively metabolized by a variety of CYP enzymes and also transported by 
genetically variable transporters. PHT shows 85-95% binding to plasma proteins 
mostly albumin. This renders PHT also an important drug interaction candidate. ADR 
range from mild to severe and are either dose-dependent or hypersensitivity 
reactions. Therefore, therapeutic drug monitoring is often required [3]. A rational 
timing for probe sampling and good interpretation of the lab data translated in optimal 
individual dosing are necessary. Therapeutic guidance especially in teaching 
hospitals are needed, have to be implemented and their usefulness if possible 
assessed. 
Bayesian Forecasting (BF) versus conventional dosing (CD): a 
retrospective, long-term, single centre analysis 
In the hospital, medication management for effective antiepileptic therapy with PHT 
often needs rapid IV loading and subsequent dose adjustment according to TDM. To 
investigate PHT performance in reaching therapeutic target serum concentration 
rapidly and in a sustainable manner, a BF regimen was compared to CD, according 
to the official summary of product characteristics. In a Swiss acute care teaching 
hospital (Kantonsspital Aarau) serving as a referral centre for neurology and 
neurosurgery, a retrospective, single centre, and long-term analysis was assessed by 
using all PHT serum tests from the central lab from 1997 to 2007. The BF regimen 
consisted of a guided, body weight-adapted rapid IV PHT loading over five days with 
pre-defined TDM time points. The CD was applied without written guidance. 
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Assuming non-normally distributed data, non-parametric statistical methods were 
used. A total of 6’120 PHT serum levels (2’819 BF and 3’301 CD) from 2’589 patients 
(869 BF and 1’720 CD) were evaluated and compared. 63.6% of the PHT serum 
levels from the BF group were within the therapeutic range versus only 34.0% in the 
CD group (p<0.0001). The mean BF serum level was 52.0 ± 22.1 µmol/L (within 
target range), whereas the mean serum level of the CD was 39.8 ± 28.2 µmol/L (sub-
target range). In the BF group, men had small but significantly lower PHT serum 
levels compared to women (p<0.0001). The CD group showed no significant gender 
difference (p=0.187). A comparative sub-analysis of age-related groups (children, 
adolescents, adults, seniors, and elderly) showed significant lower target levels 
(p<0.0001) for each group in the CD group, compared to BF. Comparing the two 
groups, BF showed significantly better performance in reaching therapeutic PHT 
serum levels rapidly and for a longer duration. 
Free PHT assessment 
However, total serum drug levels of difficult-to-dose drugs like PHT are sometimes 
insufficient. The knowledge of the free fraction is necessary upon given patient 
conditions for correct dosing. In a subgroup analysis of the above BF vs. CD study 
we evaluated the suitability of the Sheiner-Tozer algorithm to calculate the free PHT 
fraction in hypoalbuminemic patients. Free PHT serum concentrations were 
calculated from total PHT concentration in hypoalbuminemic patients and compared 
with the measured free PHT. The patients were separated into two groups (a low 
albumin group; 35 ≤ albumin ≥ 25 g/L and a very low albumin group; albumin < 25 
g/L). These two groups were compared and statistically analysed for the calculated 
and the measured free PHT concentration. The calculated (1.2 mg/L, SD=0.7) and 
the measured (1.1 mg/L, SD=0.5) free PHT concentration correlated. The mean 
difference in the low and the very low albumin group was 0.10 mg/L (SD=1.4, n=11) 
and 0.13 mg/L (SD=0.24, n=12), respectively. Although the variability of the data 
could be a bias, no statistically significant difference between the groups was found: 
t-test (p=0.78), the Passing-Bablok regression, the Spearman’s rank correlation 
coefficient of r=0.907 and p=0.00, and the Bland-Altman plot including the regression 
analysis between the calculated and the measured value (M=0.11, SD=0.28).  
Therefore, we concluded that in absence of a free PHT serum concentration 
measurement also in hypoalbuminemic patients, the Sheiner-Tozer algorithm 
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represents a useful tool to assist TDM to calculate or control free PHT by using total 
PHT and the albumin concentration.  
 
GC-MS Analysis of biological PHT samples 
To correlate PHT blood serum levels, with “brain PHT levels” representing the site of 
action of PHT, extracellular fluid from microdialysates in neurosurgical critically ill 
(ICU) patients could be analyzed for PHT by an appropriate quantifying analytical 
method, qualified and validated to be used in a clinical trial. In this investigation we 
describe the development and validation of a sensitive gas chromatography–mass 
spectrometry (GC–MS) method to identify and quantitate PHT in brain 
microdialysate, saliva and blood from human samples. For sample clean-up a SPE 
was performed with a nonpolar C8-SCX column. The eluate was evaporated with 
nitrogen (50°C) and derivatized with trimethylsulfonium hydroxide before GC-MS 
analysis. 5-(p-methylphenyl)-5-phenylhydantoin was used as internal standard. The 
MS was run in scan mode and the identification was made with three ion fragment 
masses. All peaks were identified with MassLib. Spiked PHT samples showed 
recovery after SPE of ≥ 94%. The calibration curve (PHT 50 to 1’200 ng/ml, n=6 at 
six concentration levels) showed good linearity and correlation (r2 > 0.998). The limit 
of detection was 15 ng/mL, the limit of quantification was 50 ng/mL. Dried extracted 
samples were stable within a 15% deviation range for ≥ 4 weeks at room 
temperature. The method met International Organization for Standardization 
standards and was able to detect and quantify PHT in different biological matrices 
and patient samples. The GC-MS method with SPE is specific, sensitive, robust and 
well reproducible and therefore, an appropriate candidate for pharmacokinetic 
assessment of PHT concentrations in different biological samples of treated patients. 
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5 METHODS, RESULTS AND DISCUSSION 
 
The thesis is based on three accepted, PubMed cited peer-reviewed publications. 
The full text papers are included in the text.  
The first publication refers to the retrospective analysis of Bayesian forecasting 
compared to conventional dosing of intravenous phenytoin. The second publication 
refers to the value of the Sheiner Tozer equation to calculate the free phenytoin level 
assessed in patients of the first study with measured free phenytoin levels. And the 
third publication refers to the analytical part of the thesis with the development and 
validation of a sensitive and reliable GC-MS method including clean-up for liquid 
patients’ sample to determine PHT.  
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Abstract Background In the hospital, medication man-
agement for effective antiepileptic therapy with phenytoin
(PHT) often needs rapid IV loading and subsequent dose
adjustment according to therapeutic drug monitoring
(TDM). Objective To investigate PHT performance in
reaching therapeutic target serum concentration rapidly and
sustainably, a Bayesian forecasting (BF) regimen was
compared to conventional dosing (CD), according to the
official summary of product characteristics. Setting A
500–600 bed acute care teaching hospital in Switzerland,
serving as a referral centre for neurology and neurosurgery.
Method In a retrospective, single centre, long-term analysis
of hospitalized in- and out-patients, all PHT serum tests
from the central hospital laboratory from 1997 to 2007
were assessed. The BF regimen consisted of a guided, body
weight-adapted rapid IV PHT loading over 5 days with
pre-defined TDM time points. The conventional dosage
was performed without written guidance. Assuming non-
normally distributed data, non-parametric statistical meth-
ods for analysis were applied. Main outcome measure
The extent of target therapeutic PHT serum levels
(40–80 lmol/L) was measured and compared between the
two regimens. Also, the influence of gender and age was
analysed. Results A total of 6,120 PHT serum levels (2,819
BF and 3,301 conventionally dosed) from 2,589 patients
(869 BF and 1,720 conventionally dosed) were evaluated
and compared. 63.6 % of the PHT serum levels from the
BF group were within the therapeutic range, compared with
only 34.0 % in the conventional group (p\ 0.0001). The
mean BF serum level was 52.0 ± 22.1 lmol/L (within
target range) (n = 2,819), whereas the mean serum level of
the CD was 39.8 ± 28.2 lmol/L (sub-target range)
(n = 3,301). In the BF group, men had small but signifi-
cantly lower PHT serum levels compared to women
(p\ 0.0001). The conventionally dosed group showed no
significant gender differences (p = 0.187). A comparative
sub-analysis of age-related groups (children, adolescents,
adults, seniors, and elderly) showed significantly lower
target levels (p\ 0.0001) for each group in the conven-
tional dosed group, compared to BF. Conclusion Com-
paring the two cohorts, BF with the well-defined dose
regimen showed significantly better performance in
reaching therapeutic PHT serum levels rapidly and for
longer duration.
Keywords Bayesian forecasting ! Conventional dosing !
Hospital population ! Medication management ! Phenytoin !
Therapeutic drug monitoring
Impact of findings on practice statements
• Good medication management with TDM requires a
multidisciplinary team approach.
• To give support and to take leadership for guidance in
handling, TDM, and dose adaptation of critical dose
drugs, appropriately trained pharmacy staff must be
accessible around the clock.
• Successful and sustainable adherence to therapeutic
guidelines relies on continuous use of a variety of
complementary tools (orally and written instructions,
personal intervention on the ward, data collection and
reporting).
A. Tobler ! S. Mu¨hlebach (&)
Division of Clinical Pharmacy and Epidemiology and Hospital
Pharmacy, University of Basel, Spitalstrasse 26, 4031 Basel,
Switzerland
e-mail: stefan.muehlebach@unibas.ch
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Introduction
Phenytoin (PHT) is a standard, effective and widely used
drug prescribed to prevent, control and treat epileptic sei-
zures. Although PHT use as an anticonvulsant in hospitals
is diminishing due to its complex pharmacokinetics, it is
almost the only drug authorized for seizure prevention e.g.
in neurosurgery (on-label use). PHT has been shown to
decrease the risk of post-traumatic seizures, before and
after neurosurgery in adults, and to prevent early seizures
after acute, traumatic brain injuries [1–4].
PHT’s non-linear, saturable pharmacokinetics and nar-
row therapeutic index (40–80 lmol/L and 10–20 mg/L,
respectively in serum), requires therapeutic drug monitoring
(TDM) for effective and safe usage. The established rela-
tionship between serum concentration and toxic/therapeutic
effect and the inter-individual dosage variation due to
variable metabolism and drug-interactions are further
grounds for a TDM. PHT is available as a parenteral for-
mulation enabling rapid IV loading which is often required
but difficult to manage properly [5–10]. The PHT summary
of product characteristics (SPC) provides dosing nomograms,
but IT-supported forecasting programs also exist [11–13].
Bayesian forecasting (BF) guided PHT dosing is well-
established and its clinical utility is documented [14–20].
In 1994, a rapid phenytoin IV loading regimen based on
BF was established [21]. Accompanied by a pharmacy
TDM support service it was introduced throughout the
study centre in 1997. The conventional dosing (CD)
according the product information leaflet was still in use.
The main indications for PHT treatment were the pre- and
post-operative prophylaxis of seizures e.g. in brain tumour
surgery, in patients with brain oedema or brain trauma, and
in the management of persistent seizures (status epilepti-
cus). The BF regimen consisted of a body weight-adapted
loading dose, followed by a standardized maintenance dose
period, with subsequent individually calculated mainte-
nance doses of PHT serum trough levels, according to a
protocol (see ‘‘Methods’’ section and Fig. 1). A BF pro-
gram assuming non-normally distributed population data
was introduced in which each non-steady-state serum
trough level contributes to predict the steady-state serum
concentration levels. The patient’s individual pharmaco-
kinetic parameters Km, vmax, and Vd were calculated in an
iteration process from the individual blood level measure-
ments and from the initial population kinetic values of a
general hospital patient group mostly with poly-pharma-
cotherapy and varying age and body weight [22].
Aim of the study
The aim of the present investigation was to compare and
validate the attainment of therapeutic PHT serum levels,
between a pharmaceutically supported rapid IV loading
PHT medication management using BF algorithms with
non-supported SPC nomogram-related conventional pre-
scribing, in an acute care teaching hospital. The influence
of the variables gender and age should also be assessed.
Method
Patients and data recording
Patients’ data from more than 10 years (1997–2007), was
retrospectively analyzed. A total of 6,120 PHT serum levels
(2,819 BF and 3,301 CD) from 2,589 patients (869 BF and
1,720 CD) were compared. Most patients came from neu-
rology and neurosurgery, explaining the high number of
0 16 28 5240 64 76 88 100
trough level 1 trough level 2 trough level 3
Standardised maintenance dose
(12 h-intervals)
i.v. loading
15 mg PHT/kg BW
Individual 
maintenance dose
Start of initial i.v. Infusion
[hrs]
Fig. 1 Bayesian dosing loading regimen. Loading dose: 15 mg/kg
body weight (BW) phenytoin. Standardised maintenance doses: given
every 12 h for 4–5 days, subsequently, an individually maintenance
dose was calculated. Trough levels were measured at 16, 64 h (76 h
resp.) and 88 h (100 h resp.) after starting the therapy
Int J Clin Pharm (2013) 35:790–797 791
123
Author's personal copy
patients in this study; the two cohorts were comparable in
the number of serum values and indication for IV PHT
treatment. For age-related sub-analyses, patients were
assigned to five groups (see Table 1). The BF patients’ data
were more comprehensive; they were recorded in a phar-
macy database which included the patient’s initials, gender,
age, body weight, PHT (trough) serum levels (in lmol/L),
the starting time of the initial loading dose, the time points of
PHT serum level (concentration) determination, the dose,
and TDM time point recommendations including level
forecast. Patients were encoded with an identification
number allowing anonymous data analysis. For CD patients,
only initials, gender, age, values of PHT (trough) levels
(lmol/L), and date of the PHT serum level determination
were accessible from the laboratory’s order forms. All PHT-
treated patients not registered in the BF records, were
assumed to be dosed conventionally.
Study design
The retrospective, open design, single center analysis was
carried out in a Swiss 500–600 bed acute care teaching
hospital providing internal medicine, general and special-
ized surgery, pediatrics, obstetrics and gynecology for
500,000–600,000 inhabitants. It served as a neurology and
neurosurgery referral center.
Treatment protocols
The CD group was dosed according to the manufacturer’s
SPC (Epanutin! PHT-Na, Pfizer, Zu¨rich, Switzerland;
authorized in Switzerland till 2006 or Phenhydan! PHT,
Desitin Pharma GmbH, Liestal, Switzerland) [11, 12]. The
initial daily loading dose was four times 250 mg PHT
sodium (a total equivalent to 920 mg PHT) or PHT
(depending on the selected formulation). The individual
PHT IV doses were infused every 6 h in 100 mL normal
saline over 15 min. The daily maintenance IV or p.o. dose
was three times 100 mg PHT sodium (equivalent to
276 mg PHT) or PHT. The oral dose was not corrected for
PHT’s bioavailability of 85 %. TDM serum (trough) levels
determination requests were at the physician’s discretion.
There was no pharmacy TDM support for the CD cohort.
Bayesian forecasting
The BF patients were treated according to the regimen in
Fig. 1, implemented and managed by the pharmacy, with
repetitive detailed written and oral instructions for physi-
cians and nurses. The initial loading dose of 15 mg PHT/kg
body weight was diluted in 100, 250 or 500 mL normal
saline in a concentration B7.5 mg PHT/ml; 7.5 mg PHT
acid/ml saline was shown not to precipitate in a micro-
scopic solubility test (data not shown). The loading dose
was infused over 4 h into a large central or peripheral vein
using a C20 gauge catheter for optimal tolerance. Standard
IV maintenance doses were administered over 15 min
every 12 h from day 1 to day 5; twice 175 mg PHT for
B70 kg body weight and twice 202 mg PHT for[70 kg
body weight patients, respectively. Exceptional standard
maintenance doses of 225 mg PHT and 250 mg PHT for
patients B70 kg body weight and [70 kg, respectively
were given p.o. every 12 h, compensating for the 85 %
bioavailability.
An individually calculated maintenance dose was pro-
posed starting from day 5, together with a recommendation
for the next TDM and serum level forecast. The calculation
required the patient’s body weight and the (three) TDM
levels; the 1st before the first maintenance dose (16 h after
starting the therapy), the 2nd before the morning dose on
day 4 (64 or 76 h after starting the therapy), and the 3rd on
day 5 (88 or 100 h after starting the therapy) (Fig. 1). The
calculation used a Turbo Pascal 6.0 written program and
allowed a non-steady-state approximation by iteration steps
[13]. A steady-state PHT serum concentration of 44 lmol/L
(11 mg/L) was targeted. Initial population data from S.
Vozeh and Th. Grasela were used [Vd (1 L/kg), Km (5.7
mg/L) and vmax (32.42 mg 9 (body weight)
0.6] [9–13, 21,
22]. The program calculated the patient’s individual param-
eters for vmax, Km, and Vd (with the 95 % CI), and were
filled in the TDM reporting form for the ward [13].
Treating physicians decided on the treatment protocol; it
was influenced by the pharmacy’s BF initiative. There was
no specific bias detected in the adherence to the different
protocols in the two groups.
Outcome, data analysis and statistics
All PHT levels were determined using a homogenous
enzyme immune test (EMIT, Syva corporation (Siemens
Medical Devices)) [13]. All PHT serum concentrations
assessed in the central hospital laboratory were faxed to the
Table 1 Population (number of phenytoin serum levels in the
different age groups), n = 6,120
Age class Bayesian
forecasting
(BF)
Conventional
dosing (CD)
Total
\16 years old (children) 21 138 159
16–20 years old
(adolescents)
70 60 130
21–65 years old (adults) 1,652 1,988 3,640
66–80 years old (seniors) 909 892 1,801
[80 years old (elderly) 167 223 390
Total 2,819 3,301 6,120
792 Int J Clin Pharm (2013) 35:790–797
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hospital pharmacy. All values calculated and compared
referred to PHT acid.
The primary purpose of the study was to compare the
resulting PHT serum (trough) levels with the intended
ones: primarily the proximity of PHT levels to the BF
target value of 44 lmol/L and secondly, the aim to achieve
a therapeutic PHT serum level range of 40–80 lmol/L. The
results were assessed for gender and age variables. The
investigation served as validation of the BF method,
compared to the conventional regimen (CD) in a non-
selected cohort of hospital patients (no exclusion criteria).
The STATA-program (Stata Corp., Version 10, www.
stata.com) was used for statistics. Non-normally distributed
data was assumed and therefore, non-parametric tests
applied. Pearson’s v2 distribution test and Fisher’s Exact
test (for small samples) were used for statistical significance
analyses, such as the distribution of PHT serum levels
in sub-target, target, and super-target ranges. The Mann–
Whitney U-test was used for the gender homogeneity check
and the Kruskal–Wallis-test for variance analysis of
patient’s age on measured PHT serum levels.
The box-plot presentation included mean, median and
25–75 interquartile ranges (IQR) of data; outliers were
defined as C1.5 times outside the IQR.
Ethical committee information
The retrospective analysis aimed to validate the BF PHT
IV loading regimen by comparing it with a SPC nomo-
gram-based CD, and had no influence on the PHT therapy
of the subjects investigated. There was no access to the
patients’ charts. Therefore, upon submission of the inves-
tigation to the local Ethics Committee, ethical approval
was deemed unnecessary.
Results
There was a significant difference between the two groups
in the number of serum levels within the target range
(p\ 0.0001). In the BF group 63.6 % of the levels were in
the target range and 27.5 % below, while the CD group had
only 34 % in target and 57.7 % below (Table 2).
During the entire observation period, the BF was sig-
nificantly more effective in achieving target serum levels
compared to CD (p\ 0.0001, n = 6,120), (Fig. 2). The
mean ± SD BF serum level was 52.0 ± 22.1 lmol/L (in
target) (n = 2,819) and exceeded the defined target level of
44 lM, while the respective values for CD were
39.8 ± 28.2 lmol/L (below target) (n = 3,301). The
maximal (toxic) value was 232 lmol/L in the CD group,
compared to 169 lmol/L in the BF group.
Gender analysis
In the BF group, men had minor but significant lower PHT
serum levels compared to women (p\ 0.0001), the mean
and median were always in the therapeutic range: women
(mean 53.0 lmol/L, median 53.2 lmol/L, n = 1,345) and
men (mean 51.0 lmol/L, median 50.8 lmol/L, n = 1,474).
The CD group showed no gender differences (p = 0.187);
the values for women: mean 40.6 lmol/L, median
36.3 lmol/L, n = 1,312; for men: mean 39.3 lmol/L,
median 32.7 lmol/L, n = 1,989.
Analysis of age
The overall age characteristicswere comparable, for BF:min
7.6 years, mean 57.6 years, max 92.1 years and for the CD
group: min 1.5 years, mean 54.8 years, max 100.0 years.
A comparative sub-analysis of the age-related groups
(children, adolescents, adults, seniors, and elderly) showed
significant lower target levels (p\0.0001) for each group in
the CD group compared to BF (Fig. 3).
BF validation (TDM support)
Table 3 shows the relative extent of the initially reached
target levels in the loading phase (trough levels 1–3) for
BF.
The proportion of PHT TDM levels using BF ranged
from 16.7 % (2007) to 80.3 % (2004), and from 19.7 %
(2004) to 83.3 % (2007) using CD (Fig. 4). The relative
annual proportion of BF and CD patients varied from 1:0.2
to 1:4.07.
Table 2 Distribution of phenytoin serum levels (n = 6,120): Bayesian forecasting group (n = 2,819) compared to conventional dosing
(n = 3,301)
Group Number of phenytoin serum levels (absolute and relative no.) Total
\40 lmol/L 40–80 lmol/L [80 lmol/L
Bayesian forecasting 775 (27.5 %) 1,793 (63.6 %) 251 (8.9 %) 2,819 (100.0 %)
Conventional dosing 1,904 (57.7 %) 1,122 (34.0 %) 275 (8.3 %) 3,301 (100.0 %)
Total 2,679 (43.8 %) 2,915 (47.6 %) 526 (8.6 %) 6,120 (100.0 %)
Relative values are given in brackets
Int J Clin Pharm (2013) 35:790–797 793
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Discussion
PHT TDM is well-established to control effectiveness and
toxicity in patients but interpretation of the data and dose
adaptation is difficult. Resulting medication errors are of
special concern in a teaching hospital where there are often
changes in staff and varying levels of experience. As a
consequence, appropriate medication management guid-
ance is of great importance.
The analysis of more than 6,000 PHT serum measure-
ments showed significant superiority in achieving thera-
peutic serum levels quickly (Tables 2, 3; Fig. 2) for the
pharmacy-supported BF PHT protocol compared to the
conventional, SPC-related therapeutic procedure (CD),
managed only by the prescribing physician. With the BF
protocol, the 40–80 lM target level was reached rapidly in
almost 80 % of patients after the first dose and two-thirds
remained there at the end of the initial standardized loading
phase (Table 3). The superior PHT target level achieve-
ment indicates better control of dose, Vd (body weight),
clearance, and TDM interpretation, although no exclusion
of patients for age or potentially interacting co-medications
was carried out. This proves the therapeutic appropriate-
ness of the BF protocol and its safety in not exposing
patients to toxic PHT doses in a general hospital population
(Figs. 2, 3). The study also validates the BF protocol as
opposed to the standard, nomogram-deviated CD.
Compared to CD, the superiority of BF also results from
a higher, body weight-adapted PHT loading regimen,
namely a first loading dose of 15 mg PHT/kg, followed by
a body weight-adapted standard maintenance dose. The
different IV PHT administration times—BF 4 h for the
initial loading dose versus 15 min for CD with an initial
dose of 250 mg—resulted in a significantly smaller infu-
sion rate (mg PHT/kg/min) for BF, explaining the excellent
tolerance of the higher BF dose. In contrast to CD, the
pharmacy TDM service for BF included a proposal for
dose and TDM timing, based on population data calcula-
tion, reducing also the number of meaningless PHT serum
tests [21]. The BF regimen using Bayesian algorithms and
population kinetic parameters allowed for individual cal-
culation of a non-steady state dose with even one single
TDM measurement.
Influence of gender and age
In the BF group, men had statistically significant lower
PHT serum levels compared to women (p\ 0.0001),
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Fig. 2 Box plot of mean annual
phenytoin serum levels for
Bayesian forecast (BF) and
conventional dosing (CD) from
1997 to 2007 (n = 6,120). The
therapeutic serum level range
for phenytoin (40–80 lmol/L) is
marked by the red lines.
Outliers are represented by dots
(max. values). (Color figure
online)
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Fig. 3 Phenytoin serum level and age (n = 6,120). Box plots show
the phenytoin serum levels of the Bayesian forecast group (BF) (left)
and of the conventional dosing group (CD) (right). The therapeutic
range (40–80 lmol/L) is between the red lines. Dots signify outliers.
(Color figure online)
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which may be explained by a slightly different, gender-
dependent Vd (body composition, with higher fat mass in
women). Based on this study, the gender differences are
minimal and not likely to be relevant for therapy success.
Therefore, BF can be used gender-independently.
The incidence of epileptic seizures and need for therapy
increases in people over 60 years of age, which is also
reflected in the patients investigated [23]. Literature is
inconsistent on the influence of age on PHT pharmacoki-
netics [23–27]. The elderly may have lower albumin con-
centrations (decreased plasma protein binding changes Vd)
and reduced renal drug clearance. Children, another sensi-
tive population group, show different pharmacokinetics
compared to adults [28]. However, studies were mostly
carried out with small numbers of patients, providing lim-
ited results. In this large study, the analysis of five different
age groups revealed the superiority of BF in reaching target
PHT levels, especially in patients below 20 and over
60 years of age. In the two largest groups of adults and
seniors, the CD showed a wider variation of PHT serum
levels and more outliers compared to the BF group (Fig. 3).
Age-related differences only occurred in the CD group; a
possible explanation could be the wider age range (min
1.5 years, max 100 years) compared to BF (7.7–92.1 years)
and the lower body weight-adjusted loading dose in CD. In
contrast, relevant age-related parameters such as Vd and
vmax were included in the forecasting calculation of BF.
The trend to under-dose patients in the CD group disap-
peared with increasing age of the patients. It remains to be
investigated if prescribers are more cautious in dosing the
young in absence of appropriate guidelines.
A general hospital population includes neurological
patients needing antiepileptic PHT treatment, or prevention
in emergency. Such patients often get multiple, potentially
interfering drugs also making it difficult to observe the
anti-epileptic effect, e.g. in sedated ICU patients. There-
fore, a clinical symptom-independent, lab-based PHT
concentration measurement is a reliable outcome parame-
ter. This is especially valid when investigating data from a
large sample pool over a long time period, which contrasts
Table 3 Drug concentration
range of Bayesian forecasting in
the 5 days IV loading phase:
relative distribution of
phenytoin trough levels 1–3
(day 1–5), in %; n = 1,800
Drug concentration
range
Serum trough level 1
(16 h after start of
therapy)
Serum trough level 2
(64 and 76 h resp.
after start of therapy)
Serum trough level 3
(88 and 100 h resp.
after start of therapy)
\40 lmol/L 17.3 17.7 21.3
40–80 lmol/L 78.6 72.1 66.1
[80 lmol/L 4.1 10.2 12.6
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
CD 423 312 462 503 405 343 246 145 153 169 140
BF 131 167 261 177 299 241 396 590 413 116 28
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Fig. 4 Phenytoin serum levels per year and treatment group (n = 6,120). The bars show the annual proportion of the phenytoin serum levels of
the Bayesian forecasting group (BF) and of the conventional dosing group (CD) over study period
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with the small and short-term studies comparing different
PHT dosing regimens to date [8, 14–20, 29].
A retrospective, open design was the only possibility
and provides a realistic picture of a non-study influenced
hospital situation. Nevertheless, it must be stated that a
limitation of the study design is the evaluation of lab data
without clinical assessment for effectiveness. Although it is
a suitable therapy marker not dependent on individual
medical assessments, expertise and skills, PHT TDM
cannot replace clinical outcome data [30].
The lab values included the total of all PHT serum levels
measured over more than 10 years. The extensive, labori-
ous statistical analysis of all the available variables, par-
tially missing in the incompletely defined control group (no
chart analysis) was time consuming, also delaying publi-
cation. Significant bias was likely introduced by the free-
dom of regimen choice and the monitoring options at the
discretion of the treating physician in the CD group. A
significant number of the clinicians, and certain depart-
ments did not adhere to the BF protocol, indicating the
need for continuous instruction and follow-up of medica-
tion guidance.
When comparing this investigation on more than 2,500
patients over 10 years with an initial study done in the same
setting on a much smaller number of roughly 500 patients
over 2 years, a remarkable shift from CD to BF occurred;
from 2.6:1 to 1.17:1 [21]. The increase in BF patients mir-
rored the importance of steadily instruction, follow-up and
the multimodal and multidisciplinary approach for medica-
tion management/therapeutic guidelines implementation
[31]. Pharmacy support was key to adherence to the BF
protocol. From 1997 to 2004 (after introduction and active
promotion of the BF protocol by the pharmacy with con-
tinuous and compulsory instruction and support), the annual
proportion of CD patients dropped from 76 to 20 %. After a
change in the pharmacy management in 2005 lead to lack of
promotion of the BF PHT protocol, CD increased again to
83 % in 2007 (Fig. 4).
Conclusion
IV loading with PHT for antiepileptic use is complicated,
requiring validated therapeutic guidance for successful
medication management of this critical dose drug and it’s
TDM. Nowadays, these characteristics diminish the impor-
tance of PHT.
Compared to CD, according to SPC, BF with a well-
defined PHT protocol is superior and appropriate for initial
effective and safe IV dosing and efficient TDM, in a gen-
eral hospital population.
Already (one to) three non-steady-state serum levels
allow for appropriate calculation of an individual dosage
after the initial standardized, effective 5-day PHT loading
phase in patients.
A hospital pharmacy service for TDM and the related
medication management allows for successful multidisci-
plinary implementation and follow-up of therapeutic
guidelines when continuous support and accessibility are
provided.
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Abstract Background Total serum drug levels are rou-
tinely determined for the therapeutic drug monitoring of
selected, difficult-to-dose drugs. For some of these drugs,
however, knowledge of the free fraction is necessary to
adapt correct dosing. Phenytoin, with its non-linear phar-
macokinetics,[90 % albumin binding and slow elimina-
tion rate, is such a drug requiring individualization in
patients, especially if rapid intravenous loading and sub-
sequent dose adaptation is needed. In a prior long-term
investigation, we showed the excellent performance of
pharmacy-assisted Bayesian forecasting support for opti-
mal dosing in hospitalized patients treated with phenytoin.
In a subgroup analysis, we evaluated the suitability of the
Sheiner-Tozer algorithm to calculate the free phenytoin
fraction in hypoalbuminemic patients. Objective To test the
usefulness of the Sheiner-Tozer algorithm for the correct
estimation of the free phenytoin concentrations in hospi-
talized patients. Setting A Swiss tertiary care hospital.
Method Free phenytoin plasma concentration was calcu-
lated from total phenytoin concentration in hypoalbu-
minemic patients and compared with the measured free
phenytoin. The patients were separated into a low
(35 B albumin C 25 g/L) and a very low group (albumin
\25 g/L) for comparing and statistically analyzing the
calculated and the measured free phenytoin concentration.
Main outcome measures Calculated and the measured free
phenytoin concentration. Results The calculated (1.2 mg/L
(SD = 0.7) and the measured (1.1 mg/L (SD = 0.5) free
phenytoin concentration correlated. The mean difference in
the low and the very low albumin group was: 0.10 mg/L
(SD = 1.4) (n = 11) and 0.13 mg/L (SD = 0.24)
(n = 12), respectively. Although the variability of the data
could be a bias, no statistically significant difference
between the groups was found: t test (p = 0.78), the
Passing–Bablok regression, the Spearman’s rank correla-
tion coefficient of r = 0.907 and p = 0.00. The Bland–
Altman plot including the regression analysis revealed no
systematic differences between the calculated and the
measured value [M = 0.11 (SD = 0.28)]. Conclusion In
absence of a free phenytoin plasma concentration mea-
surement also in hypoalbuminemic patients, the Sheiner-
Tozer algorithm represents a useful tool to assist thera-
peutic monitoring to calculate or control free phenytoin by
using total phenytoin and the albumin concentration.
Keywords Phenytoin ! Serum concentrations ! Sheiner-
Tozer equation ! Therapeutic Drug Monitoring (TDM)
Impact on practice
• The Sheiner-Tozer algorithm can be successfully used
to calculate a missing free phenytoin plasma concen-
tration using the total phenytoin and the albumin
plasma levels in hypoalbuminemic patients.
• The Sheiner-Tozer algorithm represents a useful and
shortly available calculation tool to assist Therapeutic
Drug Monitoring and appropriate dose adjustment of a
critical dose drug based on the free dose fraction, e.g.
& Stefan Mu¨hlebach
stefan.muehlebach@unibas.ch
1 Division of Clinical Pharmacy and Epidemiology and
Hospital Pharmacy, University of Basel, Spitalstrasse 26,
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the antiepileptic phenytoin and other highly albumin-
bound narrow therapeutic index drugs.
• The Sheiner-Tozer algorithm can be successfully
implemented for dose checking to reduce and manage
medication errors in critical dose drugs.
Introduction
Phenytoin (PHT) is a well-known antiepileptic drug which
has also shown effectiveness in post-traumatic surgery [1].
Its targeted therapeutic concentration range in blood serum
for adults and children older than three months is
10–20 mg/L (40–80 lmol/L) [2]. PHT shows 90 % plasma
protein binding corresponding to 1–2 mg/L for free PHT in
the therapeutic range. Due to its complex, non-linear and
highly variable pharmacokinetics, and its significant dose-
related toxicity, determining the correct dosage of this drug
is difficult and of critical importance for hospitalized [in-
tensive care unit (ICU)] patients. Doses higher than 20 mg/
kg in adults consistently result in clinical toxicity. Addi-
tionally, the normal lower dosage of 6 mg/kg body weight
in adults, or conventional rapid drug loading, frequently
leads to over or under dosing [2, 3]. Defining the correct
dose of PHT is challenging due to its narrow therapeutic
index, highly variable, dose-dependent, non-linear kinetics
(with elimination ‘‘half-lives’’ ranging from 16 to 60 h),
and the significant risk of drug interactions. This highlights
the importance of rapidly available Therapeutic Drug
Monitoring (TDM) for total and in selected patients-free
PHT serum concentrations in order to facilitate appropriate
and safe adjustment of the medication [4–7].
PHT fulfills the prerequisites for a useful TDM with its
narrow therapeutic index, high dose variability and most
importantly, the existing correlation between drug plasma
level and drug efficacy or toxicity. Lab testing for total
PHT in serum is routinely available in larger hospitals. In
most cases, total drug concentration in blood/plasma is
appropriate for TDM; except when the relative concentra-
tion in plasma is either too low (\50 %), or highly variable
[8]. The total concentration of drugs is easier to determine
compared to the unbound fraction, as validated methods for
the latter are only available in a few labs. In addition, tests
used to analyze total drug levels in plasma or serum are less
costly and time consuming than special analyses such as
free PHT assessment [8–10]. The concentration of the free
drug fraction is useful or required for the TDM of drugs
with narrow therapeutic index and for those with highly
variable metabolism rates affected by the patient’s genet-
ically-determined enzyme patterns. It is also useful for
medications with [90 % plasma protein binding and
variable binding plasma protein concentrations such as for
example PHT in the presence of low plasma albumin
levels.
The Sheiner-Tozer formula has been proposed to help
estimate the free PHT fraction [6]. Total PHT and the
serum albumin level must be known for this calculation. As
indicated above, hypo-albuminaemia has a significant
impact on PHT plasma protein binding and, in the end,
only the free available fraction diffuses into tissue or
organs like the brain.
Albumin concentration is influenced by diseases such as
uremia, decreased kidney function or chronic liver diseases
[8]. Albumin might also be low in elderly patients, burn
victims and/or critically ill patients, or pregnant women.
This translates into variable amounts of bound and
unbound PHT fractions as compared to a ‘‘standard’’
patient [11, 12]. A reduced bound fraction of PHT might
also result from interacting co-medications that are com-
peting for the same drug protein binding site in serum.
Acidic, highly protein-bound drugs as well as free fatty
acids are able to force PHT from the plasma protein
binding sites, resulting in higher (toxic) free PHT con-
centrations without changing total PHT concentration [8, 9,
13, 14]. The Sheiner-Tozer algorithm has been designated
to determine the free drug fraction (Fig. 1). There are
conflicting reports regarding the value of calculated free
PHT levels in patients. To further evaluate the Sheiner-
Tozer formula in clinical practice, we performed a sub-
analysis of our large, long-term PHT single center study on
an unselected group of hospitalized low albumin patients
treated with PHT, whose total and free PHT values were
also available [15].
Aim of the study
This investigation evaluated the usefulness of the Sheiner-
Tozer algorithm (Fig. 1) to calculate the free PHT dose
fraction using total PHT serum levels in unselected patients
with low albumin (\35 g/L) in a hospital setting.
Calculated free PHT =             Total PHT concentration   ×  0.1 Albumin concentration 
                44 
1.0+×9.0
Fig. 1 The Sheiner-Tozer formula: the calculated free PHT (dphCF)
[g/L] is determined with the knowledge of the total PHT (dphT) [mg/
L] and the serum albumin value of the patient. 0.9 is the protein
bound PHT fraction (90 %) and 0.1 is the free PHT fraction (10 %).
44 is the mean serum albumin value [g/L]
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Ethical approval
Additional ethical approval of this retrospective subanalysis
of the previously published and approved investigation by
the local ethics committee was deemed unnecessary, as the
investigation had no influence on the phenytoine therapy or
outcome of the anonymously investigated patients.
Method
This subanalysis was carried out as a study cohort collected
over more than 10 years and included all patients in a
tertiary care hospital who had undergone PHT serum
concentration testing. They were investigated on the value
of Bayesian PHT dose forecasting. Those patients whose
free PHT calculated concentration could be compared with
measured levels were selected [15]. All patients with a
serum albumin concentration of B35 g/L (hypo-albu-
minaemia) who had both total and free PHT serum con-
centration measurements were included. Of the initial 2500
patient cohort, 23 fulfilled these criteria. Their age ranged
from 7 to 86 years; 8 patients were male and 15 female.
The patients were hospitalized on different wards: ICU
n = 3; dialysis n = 2; surgery n = 4; internal medicine
n = 10; pediatrics n = 1; neurosurgery n = 2; orthopedic
n = 1. The patients were separated into two groups: the
low group (35 B albumin C 25 g/L, n = 11), and the very
low group (albumin\ 25 g/L, n = 12).
Total PHT in serum (dphT) was determined using a
homogenous enzyme immune test, EMIT, Syva corpora-
tion (Siemens Medical Devices) [16]. The immuno assay
produced the following precision values: Level 1: 7.9 lg/
mL, Level 2: 16.2 lg/mL, Level 3: 27.4 lg/mL. The range
of analyte values that can be measured directly from the
specimen without any dilution or pretreatment is
0.4–40.0 lg/mL. Samples with results in excess of
40.0 lg/mL were repeated on dilution. The measured free
PHT concentration in serum (dphF) was quantified from
the probe after centrifugation for 20 min (at 1000–2000g)
through a 30 kD cut-off filter to eliminate the protein-
bound fraction. Free PHT from the filtered centrifugate was
quantitated by HPLC (Agilent Technologies!). Calculation
of the free PHT fraction dphCF from the dphT was per-
formed using the Sheiner-Tozer formula (Fig. 1). This
included: serum albumin concentration, total PHT serum
concentration [dphT (mg/L)] and the theoretical unbound
serum fraction (10 % for PHT) which corresponded with
factor 0.1 in the algorithm [17]. In the formula denomi-
nator, the estimated bound fraction of PHT (90 %) is rep-
resented by factor 0.9. This bound fraction is multiplied by
the normalized serum albumin value [individual albumin
concentration (g/L) divided by the mean serum albumin
value of 44 g/L] and added to the free PHT fraction (10 %)
of 0.1 in order to determine the values for free concen-
tration in g/L.
The data was compared with the measured free PHT
concentration and statistically assessed using non-para-
metric Spearman’s rank correlation coefficient tests, t tests,
Passing–Bablok regression analyses, as well as a Bland–
Altman plot.
Results
Table 1 presents the PHT and albumin data of the 23
subjects. The following mean values and standard devia-
tions (SD) were obtained: dphT = 7.5 mg/L,
SD = 4.0 mg/L; dphF = 1.1 mg/L, SD = 0.5 mg/L;
dphCF = 1.2 mg/L, SD = 0.7 mg/L. The mean albumin
level in the patients (n = 23) was 25.5 g/L, SD = 4.7 g/L.
In the low albumin group (35 B albumin C 25 g/L), the
mean difference between dphF and dphCF was 0.10
(SD = 1.4). In the very low albumin group (\25 g/L), the
mean difference was 0.13 (SD = 0.24). An independent
sample t test revealed no significant discrepancy in the
mean differences between dphF and dphCF in the two
groups t(21) = -0.28, p = 0.78.
The prediction for the calculated free PHT (dphCF)
correlated highly with the measured free PHT (dphF); the
Spearman’s rank correlation coefficient showed a value of
r = 0.907, p = 0.00. A linear regression analysis based on
the Passing and Bablok [18] procedure further revealed that
the calculated free PHT (dphF) and the measured free PHT
(dphCF) were nearly identical (Fig. 2). Both hypotheses
b = 1 (slope value of 1 was enclosed in the 95 % confi-
dence interval) and a = 0 (the 95 % confidence interval
for the intercept contained the value 0) were accepted.
A Bland–Altman plot (Fig. 3) further supported that there
were no systematic differences between dphCF and dphF,
and a regression analysis showed no significant relationship
in the discrepancies between the measurements and the true
value (proportional bias). The regression coefficient of the
difference between the methods on the average of the two
methods was b = -0.35, p = 0.10.
Discussion
The results support and validate the use of the Sheiner-
Tozer formula to calculate free PHT concentrations in the
hospital setting, confirming its usefulness in the absence of
a free PHT determination. The data presented in this study
are comparable to a similar investigation by Dager et al.
[19], which reported a relative difference of 12.4 %
Int J Clin Pharm
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between measured and calculated values. The characteris-
tics of the two studies are also similar: 23 patients in this
study and 29 in Dager’s, and both include adults with hypo-
albuminaemia levels of \35 and \25 g/L, respectively.
The patient subgroups in this study with\25 g/L albumin
showed no significant deviation differences when com-
pared to the whole group. Hong et al. [20] presented a
much higher mean difference between measured and cal-
culated free PHT of 0.65 mg/L (SD = 0.88 mg/L), which
compromised the accuracy and the usefulness of the
results. However, our study population was different to
those in the Hong et al. investigation, as ours were Euro-
pean/Caucasian instead of Asian. This can influence the
metabolic pattern for PHT significantly due to the different
genetic effects on its drug metabolism as well as on the free
versus total PHT concentration and their kinetics. In their
study, Wolf et al. [21] determined a difference between
calculated and measured free PHT concentration of
0.31 mg/L (SD = 0.5 mg/L), which is also much higher
than the results of this study. However, they reported solely
on critically ill pediatric patients whereas we had only one
pediatric patient. We looked at a much broader range of
patients; not only with respect to age, but also severity of
disease, and individuals outside the ICU. The data vari-
ability in our patient group, also indicated by the relatively
high SD may explain why one (Bland–Altman plot) and
two (Passing–Bablok regression) of the values were outside
of the 95 % confidence interval, respectively. The values,
Table 1 Total PHT levels [dphT] and measured free PHT fractions [dphF] in the investigated 23 subjects
Nr. Total PHT level
(mg/L) [dphT]
Measured free PHT fraction
(mg/L) [dphF]
Calculated free PHT fraction
(mg/L) [dphCF]
Albumin
(g/L)
1 2.58 0.30 0.38 28
2 3.20 0.35 0.49 27
3 3.83 0.38 0.54 30
4 2.88 0.51 0.56 20
5 4.75 0.57 0.67 30
6 2.50 0.59 0.44 23
7 2.83 0.60 0.55 20
8 4.78 0.67 0.78 25
9 8.73 0.91 1.10 34
10 3.68 0.96 0.75 19
11 11.03 0.97 1.39 34
12 8.35 0.98 1.28 27
13 5.08 0.98 0.92 22
14 9.80 1.24 1.66 24
15 6.70 1.37 0.94 30
16 10.38 1.53 1.76 24
17 10.58 1.64 2.00 21
18 11.05 1.70 2.09 21
19 16.15 1.78 2.33 29
20 10.68 1.78 1.87 23
21 9.95 1.89 1.32 32
22 9.30 1.93 1.90 19
23 14.40 1.93 2.44 24
Mean 7.5 1.1 1.2 25.5
SD 4.0 0.5 0.7 4.7
Albumin\ 25 (n = 12) Albumin C 25 (n = 11) t Statistic
Independent samples t test of the mean difference between dphF and dphCF for patients with: albumin\ 25 (n = 12) compared to
albumin C 25 (n = 11)
Mean difference = 0.13
(SD = 0.24)
Mean difference = 0.10
(SD = 1.4)
t(21) = -0.28, p = 0.78.
The calculated free PHT level [dphCF] was determined according to the Sheiner-Tozer algorithm. SD Standard deviation
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however, were nearly very close to the limits of agreement
of the statistical analysis. Accordingly the Sheiner-Tozer
equation was helpful in estimating the free concentration
needed for careful dose adaptation—even in an unselected
patient group. Continuing investigations with a more
highly defined patient group could further validate the
equation for its timely and correct use in clinical settings;
especially when free drug concentrations are not available
to guide optimal dosing of such a critical dose drug.
The importance of albumin and the related binding
capacity in strongly protein bound drugs like PHT is con-
troversially discussed in the context of a PHT TDM.
According to Hong et al., hypo-albuminaemia not only
modifies the ratio of free/total PHT concentration, but also
the total PHT concentration, yielding incorrectly calculated
results. This would also explain their data, at least for the
pediatric patients [20]. They suggest determining free PHT
in hypoalbuminemic patients using a suitable lab test, but
such testing is often difficult to access or delivers data too
late to be used for timely dose modification at bedside. One
must also bear in mind that non-routine lab tests also result
in higher administrative costs (availability, time and
expenses). Therefore, such lab tests are often only ordered
in specific situations when PHT dosing problems or a lack
of drug effectiveness have occurred or is presumed. Our
study demonstrates that in such cases, a lacking free lab
PHT concentration can be calculated using the Sheiner-
Tozer formula which was useful in a general hospital
population, including patients with other potentially inter-
acting medical treatments and a variety of diseases.
According to Krasowski and Penrod [22], the Sheiner-
Tozer equation for calculating free PHT concentrations
more frequently underestimates than overestimates the
measured free PHT relative to the respective therapeutic
ranges. Nevertheless, they also conclude that if measured
free PHT concentration is not available, PHT concentra-
tion—adjusted according to the Sheiner-Tozer equation
can supplement total PHT concentration and assist proper
dosing. This was illustrated in this study on patients with
low plasma albumin, a common condition in acute care
hospitals. Our results in an unselected patient group with
partial and even severe hypo-albuminaemia showed the
Sheiner-Tozer formula to be an useful tool which yields
comparable data to specific lab testing for free PHT. This
facilitates a good TDM and provides additional informa-
tion for drug dosing. In partial contrast to the published
data, the measured free PHT concentrations values in our
(almost completely) adult patient group varied only mini-
mally. In addition, we did not detect any higher variation,
either in low or very low hypo-albuminaemia in this small
study group, nor was there a trend or indication of over-
estimation or underestimation of PHT concentrations. As a
consequence, we were able to validate the usefulness of
calculating the dphCF according to Sheiner-Tozer and can
support its use in absence of measured free PHT values for
an easy to do and appropriate dose adaptation at almost no
Passing-Bablok Regression 
Fig. 2 Results of the linear regression analysis (n = 23) based on the
Passing and Bablok [18] method, which revealed that the calculated
free PHT (dphCF) and the measured free PHT (dphF) are comparable.
Both hypotheses b = 1 (the slope value of 1 was enclosed in the 95 %
confidence interval) and a = 0 (the 95 % confidence interval for the
intercept contained the value of 0) were accepted. Slope b = 1.245,
95 % CI [0.994, 1.419]. Intercept a = -0044, 95 % CI [-0.295,
0.112]. The solid line represents the linear regression. The dotted lines
show the 95 % confidence interval
Fig. 3 Bland–Altman plot of the dphF and dphCF measurements
(n = 23). The mean difference is M = -0.11 (SD = 0.28), which is
not significantly different from zero t(22) = 0.07. The solid line
represents the mean difference. The dotted lines show the limits of
agreement (representing ±1.96 SD). In addition, regression analysis
showed a non-significant relationship in the difference between the
measured and the true values (proportional bias). The regression
coefficient of the difference between the methods on the average of
the two methods was b = -0.35, p = 0.10
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costs of hospitalized patients, when a TDM including free
PHT determination is missing.
Finally, such a tool is also helpful to avoid medication
errors in individualized patient treatment when checking a
critical PHT dosing, or even in cases of polymedication
with potentially interacting drugs, e.g. in relation to albu-
min binding despite a specific variable for interacting drugs
in the equation.
Although the subjects came from different wards and
medical disciplines, a limitation of our study is the rela-
tively small number of patients and the low number of
infants and younger children. Therefore, a comparison of
different types of subjects, for example from ICU, surgical
or internal medicine patients was not possible. To further
elucidate our findings and add necessary details, a
prospective study would assist in expanding and strength-
ening the evidence demonstrated to optimize TDM and the
use of the Sheiner-Tozer equation for critical dose medi-
cations. It could then also validate the cost-effectiveness of
the tool to avoid medication errors for better PHT man-
agement in hospitalized patients, as also indicated by von
Winckelmann et al. [23]. Such medication support could be
passed on to a multidisciplinary team and involve the
pharmacist taking responsibility for an appropriate TDM
service or to support the drugs and therapeutics committee
by implementing therapeutic guidelines. Despite potential
pharmacological interactions (most of the patients were
receiving multiple drug therapy in ICU) we were not able
to identify a distinct subgroup due to the small patient
number. The data presented only minor discrepancies and
were too variable to elucidate significant differences [see
also the Passing–Bablok regression or the Bland–Altman
plot where 2/23 and 1/23 patients felt outside of the 95 %
limit, respectively (Figs. 2, 3)]. Nevertheless, the investi-
gation indicated the potential benefit of the Sheiner-Tozer
equation and suggests its use when a specific TDM for free
PHT is not available. It provides a simple method to esti-
mate free drug concentration in the clinical setting.
Therefore and to further confirm our findings and add
necessary details, an appropriately powered prospective
study, could expand and strengthen the evidence demon-
strated to optimize TDM and its usefulness for critical dose
medications in such patients where there is a need to know
the free drug concentration in hypo-albuminaemia.
Conclusion
Calculation of free PHT concentrations using the Sheiner-
Tozer formula is a useful method to obtain additional
information from total PHT concentration values and the
albumin concentration in hypoalbuminemic patients in the
absence of a specific, potentially time-consuming and
costly free PHT determination. This study on a small group
of patients could not detect any specific difference in pre-
dicting the free PHT fraction between hospitalized patients
from different wards, and from those with differing medi-
cal conditions.
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This study describes the development and validation of a gas
chromatography–mass spectrometry (GC–MS) method to identify
and quantitate phenytoin in brain microdialysate, saliva and blood
from human samples.
A solid-phase extraction (SPE) was performed with a nonpolar C8-
SCX column. The eluate was evaporated with nitrogen (508C) and
derivatized with trimethylsulfonium hydroxide before GC–MS ana-
lysis. As the internal standard, 5-(p-methylphenyl)-5-phenylhydantoin
was used. The MS was run in scan mode and the identification was
made with three ion fragment masses. All peaks were identified with
MassLib. Spiked phenytoin samples showed recovery after SPE of
!94%. The calibration curve (phenytoin 50 to 1,200 ng/mL, n5 6, at
six concentration levels) showed good linearity and correlation (r2 >
0.998). The limit of detection was 15 ng/mL; the limit of quantification
was 50 ng/mL. Dried extracted samples were stable within a 15% de-
viation range for !4 weeks at room temperature. The method met
International Organization for Standardization standards and was able
to detect and quantify phenytoin in different biological matrices and
patient samples. The GC–MS method with SPE is specific, sensitive,
robust and well reproducible, and is therefore an appropriate candi-
date for the pharmacokinetic assessment of phenytoin concentrations
in different human biological samples.
Introduction
Epilepsy is a disorder of the central neural system characterized
by recurrent unprovoked seizures caused by excessive dis-
charge of electrical activity (1). Epilepsy can be treated with
different antiepileptic drugs that generally render 80% of
newly diagnosed patients seizure-free (2). Phenytoin (PHT)
[C15H12N2O2 (3); molecular weight: 252.3 (3)] is a well-
established antiepileptic drug designed to prevent and treat sei-
zures (4). It is routinely used on neurosurgical intensive care
unit patients with brain injuries.
PHT has a small therapeutic index; its therapeutic concentra-
tion range in blood serum is 10–20 mg/L (40–80 mmol/L) (5)
for adults and children older than 3 months. Ingestion of more
than 20 mg/kg in humans [normal oral dosage for adults is
6 mg/kg (5)] usually results in clinical toxicity (6). PHT can
produce significant dose-related toxicity because of its
complex pharmacokinetics (PK). The limited therapeutic
index, combined with the large inter-individual variability of
metabolism [half life 16–60 h, depending on plasma levels
(7, 8)], and the nonlinear pharmacokinetics of PHT (9, 10)
highlight the importance of therapeutic drug monitoring
(TDM). On the other hand, relatively few studies have been
able to demonstrate the benefits of TDM of antiepileptic drugs
(11). However, therapeutic monitoring of PHT using Bayesian
forecasting was successfully applied to rapidly achieve thera-
peutic plasma levels using an easy-to-apply PHT loading dose
regimen in a hospital setting (12).
The monitoring of brain tissue biochemistry during intensive
care cerebral microdialysis is well established (13). Samples
generated by brain microdialysis have the potential to correlate
PHT concentrations at the site of action, with plasma values
mostly used for TDM (14, 15).
The correlation of toxicity and plasma level concentration is
well established. However, the PK in critically ill patients, and
its potential change related to the characteristics of the blood-
brain barrier, contribute to the lack of understanding of the
kinetics and mode of action of antiepileptics in the brain. The
correlation between PK in blood and the target tissue in brain
is not established. To investigate correlations of PHT concentra-
tion in blood plasma, saliva (oral fluid) and tissue microdialy-
sate, a sensitive and specific analytical method is needed
(16, 17). Saliva has been shown to serve as an alternative
sample to blood plasma for TDM (18).
Commonly used analytical methods without mass spectrom-
etry (MS) detection do not reach the sensitivity needed to quanti-
tate the free fraction of PHT and the low biological PHT
concentrations (19). For clinical trials, a validated method is
required by authorities such as the Food and Drug Administration
(FDA). Gas chromatography (GC) with MS is effective and specif-
ic to separately analyze parent PHT and its metabolites (20).
However, current published GC–MS methods are not accurate
and sensitive enough to identify and quantify the expected low
levels of PHT in microdialysate samples from the human brain.
Also, the high sample volume of 500 mL used in a recently pub-
lished study is far too large for the usual microdialysis sampling in
patients, with a 2 mL/min flow rate, and therefore not appropriate
for TDM (21). GC–MS analysis needs an extraction step such as
solid-phase extraction (SPE) to clean the sample and to eliminate
interfering biological matrix materials like proteins and lipids
prior to injection into the GC–MS system. Furthermore, to detect
PHT with sufficient sensitivity by GC–MS, a derivatization of PHT
is necessary (22, 23). A structural analogue to PHT (C16H14N2O2;
molecular weight: 266.3), 5-(p-methylphenyl)-5-phenylhydantoin
(MPPH), is chosen as an internal standard (IS) (24).
The aim of the present analytical study was to establish a se-
lective and sensitive GC–MS method allowing the determin-
ation of PHT in different human biological samples, especially
in brain microdialysates. The analytical method should cover a
therapeutic range of free PHT concentration ranging from 50 to
1,200 ng/mL. A further objective of this study was to develop a
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simple and effective sample extraction method, which can be
used for different biological matrices like blood, dialysate or
saliva to reproducibly provide stable, reliable and clean analytes
for GC–MS analysis. The suitability of the analytical GC–MS
method has to be demonstrated by validation according to
International Organization for Standardization (ISO) 17025 to
be used in corresponding investigations with samples from
patients (clinical trials). The resulting analytical method is a
prerequisite for further PK and pharmacodynamic (PD)
investigations.
Material and Methods
Chemicals and samples
The PHT reference was purchased from Desitin Pharma GmbH
(Liestal, Switzerland) and from the European Pharmacopoeia
(Strasbourg, France). The IS, MPPH (C16H14N2O2; molecular
weight¼ 266.29), purity .99% was purchased from
Sigma-Aldrich Chemie (Steinheim, Germany). Calcium chloride,
citric acid monohydrate, potassium chloride, magnesium chlor-
ide hexahydrate, sodium chloride and sodium hydroxide and the
solvents methanol (MeOH), acetic acid (100%) and acetone
were of analytical grade and purchased from Merck (Darmstadt,
Germany). Trimethylsulfonium hydroxide (TMSH), 0.2M in
MeOH for derivatization, was purchased from Macherey-Nagel
(Oensingen, Switzerland). Nitrogen (analytical grade) for extract
drying, and helium (analytical grade) for GC, were obtained
from Carbagas (Liebefeld, Switzerland).
Artificial cerebrospinal fluid (aCSF), composed of 8.59 g NaCl,
0.2013 g KCl, 0.1332 g CaCl2 and 0.1758 g MgCl2 ! 6(H2O), was
prepared according to the pre-clinical device company CMA
(Stockholm, Sweden; dialysate solution) (25). CPDA-1 blood (an
anticoagulant citrate phosphate dextrose adenine solution; sub-
sequently referred to as blood plasma) was obtained from the
Blood Donor Center in Bern, Switzerland. Saliva was provided by
a volunteer. Ex situ brain tumor tissue, which had been surgically
removed from patients treated with PHT, was dialyzed against
aCSF with a flow rate of 2 mL min, yielding a sample of approxi-
mately 60 mL. Approximately 2 mL of patient CPDA-1 blood
samples with PHT were collected. Both samples (dialysates
and CPDA-1 blood) were provided by the Department of
Neurosurgery (Kantonsspital Aarau AG, Switzerland). The sam-
pling procedure was presented to the ethical committee of the
Kantonsspital Aarau, which did not require formal ethical ap-
proval because the dialysates were made ex situ. All biological
samples (CPDA-1 blood plasma and dialysate) were frozen im-
mediately after sampling at –248C. For transportation, a refriger-
ation chain (–20+28C) was guaranteed. Before extraction and
analysis, the samples were thawed at room temperature for
30 min and then vortexed for 1 min.
IS, calibrator standard solutions, quality controls,
system suitability test and sample preparation
MPPH (IS) 1 mg/mL in MeOH was prepared as a stock solution
and stored at 2–88C. This stock solution was diluted with
MeOH to 100 ng/mL for addition to solutions [internal standard
solution (ISS), 100 ng/mL]. The PHT reference stock solution
containing 1 mg PHT/mL MeOH was stored at 2–88C. To obtain
calibration standard solutions (Cals) of 1,200 (Cal 6), 1,000 (Cal
5), 800 (Cal 4), 300 (Cal 3), 150 (Cal 2) and 50 ng/mL (Cal 1),
the stock solution was diluted freshly each time with MeOH for
each measurement. To each calibrator standard (Cal), 1,200 ng/
mL MPPH (12 mL ISS) was added as IS. To each Cal, 1 mL of
biological matrix (aCSF, blood plasma or saliva) was added for
validation purposes. For quality control (QC), solutions were
prepared with 100 ng/mL (QC 1) and 1,000 ng/mL (QC 2)
PHT, also containing 1,200 ng/mL MPPH (12 mL ISS) as IS and
1 mL of blood plasma, aCSF or saliva matrix. The system suitabil-
ity test (SST) was prepared with the PHT reference solution and
IS, to a final probe of 100 ng/mL PHT and 1,200 ng/mL MPPH
(12 mL ISS).
Samples from patients were included to test the method in
real biological probes. PHT-containing microdialysis samples
(volume of 50 mL) from six patients (requiring approximately
25 min of collection time) were added to 450 mL aCSF and
1,200 ng MPPH (12 mL ISS) as IS prior to extraction. Blood
plasma samples (volume of 500 mL) from PHT-treated patients
were spiked with 1,200 ng MPPH (12 mL ISS) as IS. The
volumes of dialysate and blood were not identical to the
volumes used in the validation procedure; however, they were
useful for comparing artificial and real samples.
SPE procedure
For SPE, cartridges were used with nonpolar C8 sorbent and a
strong cation exchanger (SCX) (Bond Elute LRC Certify,
130MG; Varian). The extraction procedure is shown in Figure 1.
The method was adapted from literature (26). After equilibration
of the SPE columns with 1 mL acetonitrile for approximately
2 min, the pH was adjusted with 1 mL citric buffer, pH 5.0
(20.1 g/L citric acid, 8.0 g/L NaOH plus pH adjustment with
1 M HCl) (27). The calibrators (1 mL), QCs (1 mL) and samples
(0.5 mL) were applied to the SPE columns (Figure 1). The SPE
columns were washed with 1 mL citric buffer, followed by 1 mL
of 0.01 M acetic acid for pH adjustment (pH !3.5). After appli-
cation of a vacuum (approximately 0.5 bar) and drying for 5 min
(using a vacuum pump; Vac Master KNF LAB Laboport), PHT
was eluted with 2 ! 1 mL acetone. The columns were vacuum-
dried again for 1 min at 0.5 bar. The eluate was transferred into
a 2 mL vial and evaporated with nitrogen at 508C. The reconsti-
tution and derivatization were performed with 50 mL TMSH
immediately before GC–MS analysis at room temperature and
vortexed for 10 s (22, 28, 29).
GC–MS analysis
To demonstrate the robustness of the developed method, two
different GC–MS systems available in the same lab were used.
An HP5890 gas chromatograph was used, connected to an
HP5971 mass selective detector (with Chemstation software
supplied by Hewlett Packard). The backup system was an
Agilent 6890N/5973 Inert GC–MS. An autosampler and an in-
jector were connected to both systems (Agilent 7673 with an in-
jection syringe of 10 mL volume). Two microliters of the
prepared samples were injected to the liner prior to the GC
column. The GC column was a polysiloxane Agilent J&W
Capillary 122-5532, DB-5MS, length, 30 m; i.d., 0.250 mm; film,
0.25 mm; for temperatures from –60 to 3508C. The temperature
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program was set to 1208C for 1 min, then raised by 108C/min to
3008C and held for 6 min. The carrier gas was 99.95% high
purity helium with a flow of 1.6 mL per min. The MS systems
were on scan mode to additionally check for interfering materi-
als. The temperature of the MS detector was 1508C. The settings
for the ion source and the transfer line were 230 and 2808C, re-
spectively. The scan range was between 50 and 650 amu. The
reference window for the data analysis parameters for PHT was
2 min, with a non-reference window of 1 min. All chromato-
graphic peaks were analyzed with MassLib (www.masslib.com),
allowing mass spectra identification by both similarity and
identity. The search algorithm Search for Similar and
Identical Compounds (SISCOM) originates from Henneberg,
Weimann, and Ziegler (Max-Planck-Institute, Mu¨hlheim a.d.
Ruhr, Germany) and was developed in the 1970s (30).
Validation procedure
The validation according to ISO 17025 includes the assessment
of selectivity, accuracy, recovery of PHT after SPE, reproducibil-
ity, suitability of the calibration curves, stability of PHT and
matrix effects. Indicators for the sensitivity of the method
were the accurate assignment of the ions in different matrices
and the limit of detection (LOD) and limit of quantification
(LOQ). Blank samples from six different sources were used to
demonstrate selectivity.
Furthermore, the selectivity of the method was determined
by using the selected GC column combined with an MS detect-
or. The selectivity was verified based on the retention time and
the allocation of one quantifier ion and two qualifier ions. The
accuracy was tested at the same levels as the calibrators and
with two additional levels at QC 1 (100 ng/mL) and QC 2
(1,000 ng/mL) (n ¼ 6). Two different solutions (prepared from
different stock solutions) were used to prepare the calibration
and QC samples. The recovery of PHT was analyzed by measure-
ment of QC 1 (100 ng/mL) and QC 2 (1,000 ng/mL) (n ¼ 3),
with QC 1 (100 ng/mL) and QC 2 (1,000 ng/mL) (n ¼ 3)
without SPE. The reproducibility and suitability of calibration
curves was measured by 2 ! 3 complete series of Cal 1 to Cal 6
samples, including the extraction step. Inter-assay percent rela-
tive standard deviation (RSD), linearity and regression coefficient
were calculated. PHT stability was analyzed with QC 1 samples
after extraction for both non-derivatized [5 weeks at room
temperature (n ¼ 10)] and derivatized samples (33 h without
specific cooling). Matrix effects were analyzed by comparing the
calibration curves generated with the three matrices: aCSF
(n ¼ 6 series), blood (n ¼ 3 series) and saliva (n ¼ 3 series).
Thus, the values of each calibrator and matrix were also
compared.
Statistical methods
The statistical data were calculated with Microsoft Excel and
PASW Statistics 18.0. To show the similarity between the differ-
ent matrices, a one-way analysis of variance (ANOVA) was used.
Furthermore, for each matrix, the six calibrator levels were
checked with t-tests to determine whether the measured
values differed significantly within each level.
Results and Discussion
GC–MS analysis of PHT (separation and identification
of PHT and MPPH), retention time, ion fragment mass,
LOD and LOQ
PHT and MPPH have different, but comparable, retention times
consistent with their chemical characteristics. The GC-MS
chromatogram of PHT showed a retention time (RT) of
15.12 min and the IS has an RT of 16.15 min. The relative RT
was 1:1.015. The suitability of MPPH as IS for GC–MS analysis
of PHT was further supported by the chromatogram (Figure 2).
The observed molecular fragment masses were [280, 203, 194,
118] for PHT and [294, 203, 194, 118] for MPPH. These
minimal differences in the RT, and the comparable molecular
fragment mass spectra, illustrate the strong similarity between
the analyte PHT and the IS, MPPH. The calculation of the
sample concentration was made only with the ion fragment
masses that were identified for PHT and MPPH.
The MassLib system could easily detect PHT and MPPH sep-
arately by their mass chromatogram differences. Because of the
independence of the data type and the format of the analyte,
MassLib has been successfully used in earlier GC–MS studies,
and is now widely used as a standard to identify chemical sub-
stances in toxicology (31). Also, these results were in line with
prior studies and confirmed the suitability of this tool for the
GC–MS analytical method to identify and quantify PHT.
The LOD was calculated as signal to blank noise ratio (S/N)
(.3:1). The LOD for this method in aCSF, saliva and blood was
15 ng/mL, according to the FDA guidelines or Deutsches
Institut fu¨r Normung (DIN) standards (32, 33). Following the
Figure 1. Schematic sample process: generation of the three sample matrices,
processing during SPE and derivatization prior to GC–MS measurement.
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FDA guidelines, the LOQ was 50 ng/mL PHT and calculated as
five times the response/blank noise. Thus, the LOQ was reached
at Cal 1 level (50 ng/mL PHT). This also corresponds to the FDA
guidelines, claiming 20% reproducibility at the LOQ level (32,
33), which was reached with Cal 1.
Accuracy of the calibrators, repeatability precision
and laboratory precision
For assessment of the accuracy, the calibrators and QCs of six
individual measurements (n ¼ 6) were performed. The accur-
acy was tested with two non-identical solutions, the stock solu-
tions for calibration and the one for QC samples. The results of
the one-way ANOVA showed no significant differences for all
matrices (F ¼ 0.0002; p ¼ 0.9998). In the target range of thera-
peutic PHT concentrations in microdialysates (.50 ng/mL,
,1,200 ng/mL), accuracy was between 104.6 and 98.9%. As
expected, the largest deviation was observed at the LOQ and at
the lowest concentration level (Cal 1 at 50 ng/mL) of the cali-
bration curve, showing an accuracy value of 104.6% (Table I).
The calibrator values showed minimum and maximum percent
deviations of 20% in Cal 1, 7% in Cal 2, 3% in Cal 3, 1% in Cal
4, 9% in Cal 5, 6% in Cal 6, 12% in QC1 and 6% in QC2
(Table I). Statistically, the deviations of each concentration
value did not differ for the entire calibration, demonstrating
that there were no outliers. All of the values were within the
maximum allowed bias of 15% (32). Repeatability precision
(inter-assay variability), the minimum and maximum deviation
of all levels of measurements, was within 15% of the coefficient
of variation (CV) (Table I).
Regarding laboratory precision (intra-assay variability), for
the QC 1 and QC 2 measurements (n ¼ 6), the mean percent
deviation from the target value was 2.7% for QC 1 (100 ng/mL)
and 0.6% for QC 2 (1,000 ng/mL). As with the calibrators, the
QC 1 and QC 2 also showed a deviation from the nominal
value of less than 15% CV. These results support the robustness
of the method. Neither the operator nor the day of preparation
influenced the results in a detectable manner. There was no
difference in the characteristics of the chromatogram when
changing from the GC–MS HP system to the backup (Agilent
Systems). The laboratory in which the investigations were
made is part of the forensic laboratories in Switzerland and
takes part in all necessary proficiency tests to be ISO 17025
certified.
Linearity and regression coefficient of calibration curve
The linearity of the calibration was tested with replicates of Cal
samples for the PHT concentration range of 50 to 1,200 ng/mL
in aCSF (n ¼ 6), saliva (n ¼ 3) and blood (n ¼ 3). As shown in
Table I, the calibration curve for PHT showed a linear regres-
sion coefficient (r2) greater than 0.998 (r2blood plasma ¼ 0.998,
r2dialysate ¼ 0.999 and r2saliva ¼ 0.999) in all three matrices, indi-
cating excellent linearity in the target concentrations (Table I).
The calculations, including the linearity check of the calibra-
tion curves, were directly conducted by the ChemStation
software.
The one-way ANOVA showed no statistically significant differ-
ences in calibrator-spiked samples of the different matrices: F ¼
0.0002, p ¼ 0.999. Each calibrator level was tested for consist-
ency using a t-test. The t-test showed no statistically significant
deviation at each calibration level. This allows for the validation
procedure to be simplified by analyzing only one matrix and ex-
trapolating the results to the other matrices. It is standard that
the deviation of the lowest Cal from the nominal value should
be within +20%. For all other Cals, the deviation from the
nominal value should be within +15%, as required by FDA
Figure 2. Total ion chromatograms (TICs) and MS fragment spectra of PHT (50 ng/mL) and MPPH (1,200 ng/mL). GC–MS chromatograms: (A) PHT; (B) IS MPPH; (C) MS
fragments and a 2.0 mL injection of a 50 ng/mL PHT solution LOQ; (D) time-related peaks and 1,200 ng/mL MPPH. (A) The ion fragments for PHT are [280,203,194,118], (C)
RI33: TIC chromatogram; chromatograms of the mass fragments at m/z 280, 203 and 194 and (B) for MPPH the fragments are [294,203,194,118], (D) RI33: TIC chromatogram;
chromatograms of the mass fragments at m/z 294, 217 and 208.
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Table I
Calculated Data from the Measurements with aCSF as Matrix and Arithmetic Mean of the Calibrators in Different Matrices*
Calculated data from the measurements with aCSF as matrix
Sample name Overall mean SD Mean deviation (%) Inter-assay CV
(%)
Accuracy
(%)
Cal 1 (50 ng/mL) 52.3 6 9.65 11.5 104.6
Cal 2 (150 ng/mL) 152.5 16.9 7.51 11.1 101.7
Cal 3 (300 ng/mL) 296.7 33.3 9.33 11.2 98.9
Cal 4 (600 ng/mL) 597 55 6.75 9.2 99.5
Cal 5 (1,000 ng/mL) 996 48 3.55 4.8 99.6
Cal 6 (1,200 ng/mL) 1,220 65 4.46 5.3 101.7
QC 1 (100 ng/mL) 102.7 6 2.7 6.3 102.7
QC 2 (1,000 ng/mL) 1,005.7 35 0.6 3.6 100.6
Arithmetic mean of the calibrators in different matrices
Calibrator (concentration) aCSF mean/deviation from target concentration
(n ¼ 6)
Saliva mean/deviation from target concentration
(n ¼ 3)
Blood plasma mean deviation from target concentration
(n ¼ 3)
Cal 1 (50 ng) 52.3/20% 42.8/14.4% 42/16.0%
Cal 2 (150 ng) 152.5/7% 153/05.7% 154.6/4.8%
Cal 3 (300 ng) 296.7/3% 287.8/6% 296.8/3.9%
Cal 4 (600 ng) 597/1% 612 /1.9% 627/4.5%
Cal 5 (1,000 ng) 996/9% 998/1.7% 972/6.67%
Cal 6 (1,200 ng) 1,220/6% 1,206/1.1% 1,194/0.7%
Linear best fit aCSF Saliva Blood plasma
Coefficient of determination (r2) 0.999 0.999 0.998
y-intercept 0.288 3.818 5.542
Slope (x) calibration 1.006 1.002 0.989
*Note: All samples were spiked with PHT. Mean deviation (%): mean percent deviation from target, inter–assay; CV (%): inter-assay percent RSD; accuracy (%): accuracy calculated out of each sample group in percent (n ¼ 6 for all samples).
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guidelines (32). The presented method fulfilled these require-
ments and even performed superiorly.
SPE; recovery with and without SPE
To produce reproducible GC–MS data from biological samples,
an appropriate clean-up procedure of the samples is necessary
to eliminate the matrix components that may potentially inter-
fere with the analysis, to maintain the responsiveness, and to
keep the method consistent and reliable, even after larger
series of sample analyses. SPE is widely used for the extraction
procedure in GC–MS analyses. SPE columns are commercially
available, which allows high-grade and reproducible quality
characteristics. The mixed-mode silica SPE columns used in
this investigation are also frequently used in forensic toxicol-
ogy to extract basic and cationic drugs, and are also very effect-
ive for the extraction of a wide range of compounds from
aqueous matrices like urine, dialysate or blood (34). They are
appropriate for small sample volumes and low concentrations
of the investigated substances (28, 29), as was the objective
in this study.
A single extraction required 40 min, including the time for
admixing the solvents, equilibration, flow through the sorbent
and drying of the eluate. This indicates that the method is not
intended for routine serial TDM analyses, but fulfils the require-
ments for research.
The recovery was analyzed by the measurement of spiked
QC 1 and QC 2 samples extracted in SPE columns, compared
with spiked QC 1 and QC 2 samples without extraction. The
difference between the PHT values of QC 1 and QC 2 with and
without SPE was within an 8% range for QC 1 and 6% for QC
2, which demonstrates the efficiency and reliability of the SPE
(n ¼ 3). The inter-assay CVs (%) of the recovery were 15% for
QC1 and 2% for QC2. The recovery of more than 90% of
the spiked samples was consistent and reproducible (n ¼ 6)
and demonstrated that the SPE columns are suitable for the
extraction of PHT from biological samples such as human
blood plasma, saliva or brain microdialysate (32). The amount
of PHT recovered after SPE was 94.1% for 100 ng/mL and
94.3% for 1,000 ng/mL, compared to the amount found in
unextracted QC samples (100%) (n ¼ 3).
Stability of the extracted PHT samples
The stability of the processed samples was tested over time by
preparing and extracting QC 1 10 times. The eluate was evapo-
rated (Figure 1) and the dried QC 1 samples were stored at
room temperature. These samples were derivatized with TMSH
at Weeks 0, 2, 3, 4, and 5 and measured immediately after deri-
vatization. The variations of the measured concentration over
time were within 15%. No significant changes, deviation or
trend for degradation were detectable in the GC vials during
storage. This leads to the conclusion that the dried PHT eluate
was highly stable at room temperature and no time-dependent
degradation occurred during the 5 weeks. In practical terms,
these results demonstrate that the processed PHT samples
(cleaned up) are stable and can be stored at room temperature
without loss of PHT before TMSH derivatization for the
GC–MS analyses.
The short time stability testing of derivatized QC samples,
stored without artificial cooling at ambient temperature of ap-
proximately 308C, performed three times at 0, 23 and 33 h,
showed an even smaller deviation than those in the underiva-
tized study over 5 weeks. The deviations from the first meas-
urement were within 4% at 100 ng/mL and 1% at 1,000 ng/mL.
There was also no statistically significant decrease in the con-
centrations of PHT or IS over time, demonstrating the stability
of the derivatized samples over at least 24 h at slightly elevated
temperatures (e.g., in a probe tray or autosampler), even when
the vial cap was perforated by the injection needle. The ana-
lysis of the underivatized stored samples after SPE showed at
100 ng/mL a deviation from the first measurement within 3%,
and at 1,000 ng/mL a deviation of 5%. The stability data from
the derivatized and non-derivatized groups that were simultan-
eously assessed showed no significant variations between the
groups. Therefore, biological PHT probes (after SPE and evapor-
ation) are very stable at room temperature over more than a
month, and are not affected by conditions encountered in an
ordinary analytical lab. No specific storage precautions are
needed.
Selectivity and specificity
The selectivity and specificity were demonstrated in all three
matrices (blood plasma, dialysate and saliva) by good peak dif-
ferentiation and quantification of PHT. Both the blank biological
samples without IS and those with IS were negative; hence, any
false positive blank samples could be excluded (aCSF: n ¼ 6;
saliva: n ¼ 3; blood plasma: n ¼ 3).
Samples from patients receiving PHT
To test the method on real human biological samples, ex situ
brain tumor microdialysates and blood samples from six patients
treated with PHT were analyzed. The volumes of dialysate and
blood were not identical to the sample amount in the validation
(described previously). Nevertheless, the first indication on the
use of the method was observed in non-spiked biological
samples (patients’ probes). The results of the dialyses samples
were (in ng/mL) 54.8 for Patient 1, 162.6 for Patient 2, 45 for
Patient 3, 63.4 for Patient 4, 353.2 for Patient 5 and 661 for
Patient 6. The corresponding blood values (in ng/mL) were
2,245 for Patient 1, 3,078 for Patient 2, 5,676 for Patient 3,
19,073 for Patient 5 and 16,349 for Patient 6. No blood was avail-
able from Patient 4. The blood and dialysate data from the indi-
vidual patients were consistent. Only 1–5% of blood plasma in
brain ex situ dialysates resulted, which corresponds to approxi-
mately half of the assumed free serum PHT concentration (10%
free PHT in plasma). The measured PHT concentrations were in
the tested range of the method. It has to be speculated that in
the monitored ICU patients, either steady-state conditions
in the brain (deep compartment) were not yet achieved, or
other specific PK conditions existed, indicating a more compli-
cated extrapolation from plasma to the brain values (blood-
brain-barrier or leaking central compartment). No saliva (oral
fluid) samples were collected and analyzed from patients. The
results show the importance of testing and validating a new
TDM analysis. The need for parameter validation, including
correct modeling of data, is crucial for reliable drug
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concentration tracking in biological materials intended to inves-
tigate PK/PD correlations in such critical patients. Such studies
could result in safer, more efficacious and rational drug dosing
in patients.
Conclusions
The goal of the study was to establish a selective and sensitive
GC–MS method that allows for the determination of PHT in
different biological samples matrices such as blood plasma,
saliva or brain microdialysate for TDM and related PK/PD
investigations.
The robustness of the method was illustrated by using two
different analytical systems, which did not show any differences
in the response and results. There was no deviation between
the measurements made for the calibration curve with different
matrices, and furthermore, the QC of the measurements with
different matrices also showed no differences. The presented
method has been proven for PHT detection and quantification
in the aimed investigated human biological matrices. This
reveals the exemplary robustness of the method.
The cleaned samples are stable for at least one month at
room temperature before derivatization for GC–MS. They were
stable for more than 30 h in derivatized form, ready to be ana-
lyzed in an autosampler. The LOD (15 ng/mL) and the LOQ
(50 ng/mL) meet the requirements of FDA guidelines and the
method meets analytical standards according to ISO 17025.
Therefore, the method is suitable for assessing PHT in different
tissues, including liquor/brain microdialysate at therapeutic
concentrations (100–200 ng/mL). The method might be of
primary interest for research purposes such as toxicity, clinical
trials or PK/PD investigations of patients in critical care with
brain surgery/trauma in which microdialysis is used.
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6 CONCLUSIONS 
 
Bayesian Forecasting (BF) versus conventional dosing (CD): a 
retrospective, long-term, single centre analysis 
Correct PHT dosing and administration is difficult and prone for inappropriate or even 
incorrect procedures (medication errors) which are also characteristic for narrow 
therapeutic dose drugs. In hospitals, rapid IV loading of PHT as antiepileptic is often 
necessary but should be individualized and accompanied by a validated therapeutic 
guidance including TDM recommendations and proper support to interpret the data 
[1-6]. As shown in this long-term investigation, BF together with a strict and detailed 
PHT dosing/infusion protocol is by far superior to CD. The presented regimen 
includes an initial high (15mg/kg body weight) IV loading dose over a defined slow 
infusion period. It is well-tolerated and accompanied by a rational TDM and is suited 
for the clinical setting. With only the body weight of the patient, appropriate 
population data, and one to three non-steady-state serum level determinations during 
the loading phase an accurate BF of an individual PHT dosage is provided in almost 
all hospitalized patients. The initial standardized high dose PHT loading over five 
days was effective and safe. The TDM lab service together with the medication 
support service from the hospital pharmacy allowed a successful multidisciplinary 
implementation and follow-up of the therapeutic PHT guidelines. Continuous support, 
active teaching and accessibility of this dosing support are necessary because of the 
rapidly changing trainee staff in a teaching hospital as also demonstrated in this 
study. BF is powerful and efficient for drug dosing and TDM for both, the routine 
(chronic) treatment and also the extraordinary case (emergency, ICU).  
 
Recommendations from the investigations 
x BF patients showed tremendously improved therapeutic PHT serum levels 
compared to CD patients. This can only be achieved and maintained in a 
teaching hospital by a permanent instruction, follow-up and an 
interprofessional approach for the medication management [7]. Nevertheless, 
additional prospective investigations with outcome-measurements (e.g. 
morbidity like seizures, length of hospitalisation etc.) are needed to correlate 
the improved serum levels also with clinical outcome. 
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x The large data set from this long-term investigation could be used to generate 
new and even better (hospital focussed) population data. Such Michaelis-
Menten parameters (Vd, vmax, Km) from adults incremented by data from 
children would foster the proposed regimen (see below). 
x Children (≤40 kg body weight) represented only a small group in this study, 
and should be studied in-depth to evaluate e.g. for a (lowered) maintenance 
dose in this sensitive group of patients. 
x Special care has to be given for the interpretation of serum levels in the elderly 
to respect the altered pharmacokinetics like reduced albumin concentrations, 
diminished efficiency of drug metabolism (CYP-enzymes). In this cases, the 
Bayesian forecasting is superior, because it calculates further parameters 
changing with age such as Vd and Km. 
x The interprofessional collaboration between laboratory, hospital pharmacy, 
medical and nursing staff improves the efficiency and correctness of difficult to 
dose drugs such as PHT. 
x A patient-centred but also pharmacological input especially in the absence of 
clinical pharmacology service on site can be timely provided from the 
appropriately trained hospital pharmacy team to support a rational and safe 
drug use in difficult drug therapies as also included in the overarching 
statements of the International Pharmaceutical Federation (FIP) to provide 
good pharmacy practice (GPP), good trade practice (GTP), good 
manufacturing practice (GMP) and good distribution practice (GDP) together 
with good procurement practice to the point of care in multiprofessional teams 
to improve treatment results and patient-benefit [8]. 
x TDM in the interdisciplinary collaboration between the clinics and the hospital 
pharmacy can efficiently support the rational and good drug use and has to be 
considered when using drugs like PHT with a narrow therapeutic range. 
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Free PHT assessment 
Total PHT serum levels are well established and used. But they don’t reflect the 
effective free drug concentration relevant at the site of action (brain). Calculation of 
free PHT concentrations using the Sheiner-Tozer formula is a useful, quick and an 
easy method to obtain necessary additional information from total PHT and the 
albumin concentration in hypoalbuminemic patients in the absence of a specific, 
potentially time-consuming and costly free PHT determination to avoid medication 
errors for better PHT management in patients [9]. This investigation in a small group 
of patients could not detect any specific difference in predicting calculated free PHT 
fraction between hospitalized patients from different wards, and from those with 
different medical conditions nor in relation to low or very low albumin levels compared 
to measured free PHT levels. 
 
 
 
 
Recommendations 
x The Sheiner-Tozer equation supports a calculation of free PHT concentration 
from only measured total PHT and the known albumin concentration in a 
simple and rapid way when a free PHT determination is lacking.  
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GC-MS Analysis of biological PHT samples 
A selective and sensitive GC–MS method has been developed and validated that 
allows the determination of PHT in different biological sample matrices such as blood 
plasma, saliva or brain microdialysate for TDM and related PK/PD investigations. The 
LOD (15 ng/mL) and the LOQ (50 ng/mL) meet the requirements of the FDA 
guidelines or of the Deutsches Institut für Normung (DIN) standards. The method 
meets analytical standards according to ISO 17025 [10-11]. Therefore, the method is 
suitable for assessing therapeutic concentrations (100–200 ng/mL) of PHT in 
different tissues, including liquor/brain microdialysate sometimes available in 
neurosurgical service.  
The sample preparation and clean-up using SPE was efficient, reproducible and 
showed an almost complete recovery of > 94%.  
The analytical GC-MS method fulfilled the requirements for a selective, sensitive, 
linear, precise, stable, reproducible and robust analysis suitable for the determination 
of (free) PHT in the CNS-dialysate. 
 
Further studies 
x The defined analytical method and their validation represent as a base to 
further investigate PHT in (human) biological samples (blood, saliva,…) with 
primary scientific interest e.g. in the PK-PD area in patients. 
x The method should be further evaluated with other analytical and detection 
systems like LC-MS to get a robust, simple and economic analysis also to 
simplify and e.g. to eliminate a clean-up step of the samples when using 
patient samples. 
x The correlation of PHT concentration in the serum and the extracellular fluid 
will be further investigated also using kinetic modelling to assess the power of 
serum TDM also in specific patient groups (thesis Raphael Hösli). 
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